Dr Andreas Vogel | Head of European Regulatory
Bluebird Bio

Dr Andreas Vogel, Head of European Regulatory, Bluebird Bio

Andreas Vogel, Ph.D., is Senior Director, Regulatory Science at bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies. A developmental biologist by training, he joined the pharmaceutical and biotech industries in 2001 as a researcher at Exelixis (Germany) before changing to Regulatory Science in 2004. He has held positions at F. Hoffmann-La Roche, Voisin Consulting Life Sciences and Laboratoires CTRS. At bluebird bio, Andreas has been heading the European Regulatory team since 2017.


Day 2, Nov 8 @ 09:25

Speaking from experience, expedited regulatory pathways in gaining EMA PRIME examples – Where do we go from there?

  • Paving the way for biotechs to gain approval and access
  • Recent changes and future amendments to regulatory issues surrounding orphan drugs approval
  • How are companies interacting the payers and how to close the gap to allow treatments to reach patients
Discussion with payer and PRIME designated companies
last published: 17/Oct/18 12:05 GMT

back to speakers

Follow us on


Sign Up for Event Updates

Get Involved At World Orphan Drug Congress 2018


To Sponsor Or Exhibit


Andrew Mears
t/ +44 20 7092 1228


To Speak


Wing-Yun Cheung
t/ +44 20 7092 1172


To Register


Issa Mauthoor
t/ +44 20 7092 1257